Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FES | P07332 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | MARK3 | P27448 | 1/20 | 0.67 |
| ▸ | TYK2 | P29597 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | SYK | P43405 | 1/20 | 0.67 |
| ▸ | CLK2 | P49760 | 1/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 4/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PTAFR | P25105 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12335083 | 1.00 | FES (0.67) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12335052 | 1.00 | FES (0.67) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL14324785 | 0.93 | NAMPT (0.62) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12336100 | 0.91 | FES (0.63) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12334916 | 0.90 | FES (0.61) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12335516 | 0.88 | KDM4E (0.51) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12335114 | 0.88 | KDM4E (0.51) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12336172 | 0.88 | NOTUM (0.58) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12335427 | 0.87 | KDM4E (0.52) | FESRETMARK3TYK2FLT4 | |
| SCHEMBL12335079 | 0.85 | NOTUM (0.60) | FESRETMARK3TYK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | FES 4094/4885RET 2381/4885MARK3 2068/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | FES 4391/4885RET 1129/4885MARK3 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.